Exelixis: Speeding Towards Becoming a Top-Tier Biopharmaceutical

Watching the outperformance of the new approaches for cancer immunotherapies, especially the checkpoint inhibitors and other immunotherapy successful attempts, oncologists recognized that the ultimate efficacy of empowering the immune system to fight cancer will be reached when immunotherapy products are combined with other suitable products. In this respect, researchers and oncology specialists seem to believe that targeted therapeutics could be among the most fitting products for combination with immunotherapy products. We believe that firms such as Exelixis, Array, Seattle Genetics, and Incyte have targeted products that are suitable for use in combination with immunotherapy . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.